Ignite Creation Date:
2025-12-25 @ 3:37 AM
Ignite Modification Date:
2026-05-21 @ 4:51 AM
Study NCT ID:
NCT04540705
Status:
COMPLETED
Last Update Posted:
2024-02-28
First Post:
2020-09-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Sponsor:
Bristol-Myers Squibb
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CA045-011
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |